AMANDA SHACKELFORD: Open Payments
NPI 1295460251 · NICHOLASVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,100 in 57 payments from 16 companies in 2025. Trend: 2023 $570 · 2024 $959 · 2025 $1,100
Food & beverage: $1,088Education: $12
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 14 | $252 |
| Novo Nordisk Inc | 10 | $233 |
| Lilly USA, LLC | 9 | $232 |
| Gilead Sciences, Inc. | 5 | $87 |
| GlaxoSmithKline, LLC. | 4 | $65 |
| Edwards Lifesciences Corporation | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 5 | $26 |
| Verona Pharma, Inc. | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| PFIZER INC. | 1 | $23 |
Products named: OTEZLA, MOUNJARO, Ozempic, ZEPBOUND, Rybelsus, TRELEGY ELLIPTA, REPATHA, SAPIEN 3 Ultra RESILIA.
Industry payments across KY — which companies pay providers there.
